Baseline hyper-eosinophilia: A possible predictor of hyper-progression
in a patient with metastatic lung adenocarcinoma treated with
Immune Checkpoint Inhibitors (ICI) were shown to improve survival in
patients with advanced non-small cell lung cancer. Nevertheless, around
10% of treated patients may have an atypical response with disastrous
tumor growth and earlier death. Readily available predictors of such
response are still unrevealed and desperately needed.